Theresa M. LaVallee
Corporate Officer/Principal bei COHERUS BIOSCIENCES, INC.
Profil
Theresa M.
LaVallee is currently the Chief Development Officer at Coherus BioSciences, Inc. She previously worked as a Senior Director of Translational Medicine at MedImmune LLC, a Senior Director of Cell Biology at CASI Pharmaceuticals, Inc., a Vice President of Translational Medicine at Kolltan Pharmaceuticals, Inc., a Senior VP of Regulatory & Precision Medicine at Celldex Therapeutics, Inc., and a VP of Translational Medicine & Regulatory Affairs at The Parker Institute For Cancer Immunotherapy.
LaVallee holds a doctorate from the University of California, Los Angeles and an undergraduate degree from the University of California, Santa Barbara.
Aktive Positionen von Theresa M. LaVallee
Unternehmen | Position | Beginn |
---|---|---|
COHERUS BIOSCIENCES, INC. | Corporate Officer/Principal | 17.12.2021 |
Ehemalige bekannte Positionen von Theresa M. LaVallee
Unternehmen | Position | Ende |
---|---|---|
The Parker Institute For Cancer Immunotherapy
The Parker Institute For Cancer Immunotherapy Miscellaneous Commercial ServicesCommercial Services The Parker Institute for Cancer Immunotherapy is a research organization that aims to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases. The Parker Institute for Cancer Immunotherapy is based in San Francisco, CA. The private company conducts clinical trials to tackle the toughest cancers and answer the hardest questions in immunotherapy. The institute coordinates cancer research efforts between the best scientists, clinicians, and partners in the industry. The company has legal experts who help their researchers navigate the intellectual property process and turn their cancer immunotherapy discoveries into treatments. It was founded by Sean N. Parker, Adam Kolom, Michael Polansky. | General Counsel | - |
CELLDEX THERAPEUTICS, INC. | General Counsel | - |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
CASI Pharmaceuticals, Inc. /Old/
CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | Corporate Officer/Principal | - |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Corporate Officer/Principal | - |
Ausbildung von Theresa M. LaVallee
University of California, Los Angeles | Doctorate Degree |
University of California, Santa Barbara | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
CELLDEX THERAPEUTICS, INC. | Health Services |
COHERUS BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Health Technology |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
CASI Pharmaceuticals, Inc. /Old/
CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | Health Technology |
The Parker Institute For Cancer Immunotherapy
The Parker Institute For Cancer Immunotherapy Miscellaneous Commercial ServicesCommercial Services The Parker Institute for Cancer Immunotherapy is a research organization that aims to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases. The Parker Institute for Cancer Immunotherapy is based in San Francisco, CA. The private company conducts clinical trials to tackle the toughest cancers and answer the hardest questions in immunotherapy. The institute coordinates cancer research efforts between the best scientists, clinicians, and partners in the industry. The company has legal experts who help their researchers navigate the intellectual property process and turn their cancer immunotherapy discoveries into treatments. It was founded by Sean N. Parker, Adam Kolom, Michael Polansky. | Commercial Services |